首页|COVID-19 vaccine updates for people under different conditions

COVID-19 vaccine updates for people under different conditions

扫码查看
原文链接
  • 万方数据
SARS-CoV-2 has caused global waves of infection since December 2019 and continues to persist today.The emergence of SARS-CoV-2 variants with strong immune evasion capabilities has compromised the effectiveness of existing vaccines against breakthrough infections.Therefore,it is important to determine the best utilization strategies for different demographic groups given the variety of vaccine options available.In this review,we will discuss the protective efficacy of vaccines during different stages of the epidemic and emphasize the importance of timely updates to target prevalent variants,which can significantly improve immune protection.While it is recognized that vaccine effectiveness may be lower in certain populations such as the elderly,individuals with chronic comorbidities(e.g.,diabetes with poor blood glucose control,those on maintenance dialysis),or those who are immunocompromised compared to the general population,administering multiple doses can result in a strong protective immune response that outweighs potential risks.However,caution should be exercised when considering vaccines that might trigger an intense immune response in populations prone to inflammatory flare or other complications.In conclusion,individuals with special conditions require enhanced and more effective immunization strategies to prevent infection or reinfection,as well as to avoid the potential development of long COVID.

SARS-CoV-2vaccinevariants of concernelderlyimmunocompromised

Yijiao Huang、Weiyang Wang、Yan Liu、Zai Wang、Bin Cao

展开 >

National Center for Respiratory Medicine

State Key Laboratory of Respiratory Health and Multimorbidity

National Clinical Research Center for Respiratory Diseases

Institute of Respiratory Medicine,Chinese Academy of Medical Sciences

Department of Pulmonary and Critical Care Medicine,Center of Respiratory Medicine,China-Japan Friendship Hospital,Beijing 100029,China

School of Basic Medical Sciences,Tsinghua Medicine,Tsinghua University,Beijing 100084,China

Tsinghua University-Peking University Joint Centre fo

Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China

Department of Infectious Disease,The Affiliated Yantai Yuhuangding Hospital of Qingdao University,Yantai,Shandong 264000,China

Institute of Clinical Medical Sciences,China-Japan Friendship Hospital,Beijing 100029,China

Tsinghua University-Peking University Joint Centre for Life Sciences,Tsinghua University,Beijing 100084,China

Peking Union Medical College,Chines

展开 >

2024

10.1007/s11427-024-2643-1

中国科学:生命科学(英文版)
中国科学院

中国科学:生命科学(英文版)

CSTPCD
影响因子：0.806
ISSN：1674-7305
年,卷(期)：2024.67(11)